Innovation Pharmaceuticals Inc (IPIX)

[djs7]

My thought would be someone runs the trial and an interim analysis is done after 200 patients. If results not showing grade 3/4 OM prevention, and reduction in days having severe OM, then rest of trial is scrapped.
Question is would the party paying for the trial owe money for the rest of the trial that was never run?
I would think no payment required for not running remaining part of the trial. Trial would be halted.

Soligenix is running their IV Delivery OM Phase 3 and their Phase 2 did not show prevention of OM, nor does their clinical trial endpoint for Phase 3 show OM prevention.